K
Kitty J. Jager
Researcher at University of Amsterdam
Publications - 290
Citations - 12189
Kitty J. Jager is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Population & Dialysis. The author has an hindex of 56, co-authored 239 publications receiving 9705 citations. Previous affiliations of Kitty J. Jager include Public Health Research Institute & Amsterdam University College.
Papers
More filters
Journal ArticleDOI
Survival analysis: time-dependent effects and time-varying risk factors
Friedo W. Dekker,Friedo W. Dekker,Renée de Mutsert,Paul C. W. van Dijk,Carmine Zoccali,Kitty J. Jager +5 more
TL;DR: In this paper, short-term versus long-term effects (so-called time-dependent effects) of a fixed baseline risk factor are addressed and an example is presented showing that underweight is a strong risk factor for mortality in dialysis patients, especially in the short run.
Journal ArticleDOI
Competing risks analyses: objectives and approaches
Marcel Wolbers,Michael T. Koller,Vianda S. Stel,Beat Schaer,Kitty J. Jager,Karen Leffondré,Georg Heinze +6 more
TL;DR: This work gives a non-technical overview of competing risks concepts for descriptive and regression analyses and introduces regression models for the cumulative incidence function and the cause-specific hazard function, respectively.
Journal ArticleDOI
Selection bias and information bias in clinical research.
TL;DR: Two categories of bias are focused on: selection bias and information bias which may affect the internal validity of a clinical study.
Journal ArticleDOI
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA.
Alberto Ortiz,Mario Cozzolino,Raphaël Duivenvoorden,Danilo Fliser,D. Fouque,Casper F. M. Franssen,D. Goumenos,Marc H Hemmelder,Luuk B. Hilbrands,Kitty J. Jager,Ziad A. Massy,Marlies Noordzij,Alexander R. Rosenkranz,María José Soler,Kathryn K. Stevens,Roser Torra,Serhan Tuglular,Priya Vart,C Wanner,R. T. Gansevoort +19 more
TL;DR: In this paper, the authors defined essential action points (summarized in Box 1), among which is advocating the inclusion of CKD patients in clinical trials testing the efficacy of drugs and vaccines to prevent severe COVID-19.
Journal ArticleDOI
External validation of prognostic models: what, why, how, when and where?
TL;DR: Clinicians and researchers are enabled to gain a deeper understanding of how to interpret model validation results and how to translate these results to their own patient population.